Healthcare And Biotechs Feel The Heat As The Market At New Highs

The steady gain reflects a diminishing concern relating to the pace of a global economic slowdown, as major central banks and governments have moved to bolster growth. The Federal Reserve has been relatively aggressive in adjusting its policy this year after recognizing the potential risks to economic growth. At the same time, the Chinese economy is beginning to reveal signs of bottoming out as the government begins to boost infrastructural and stimulus spending. The ECB has been equally sensitive about signs of an economic slowdown and has indicated a patient approach. This almost concerted effort in key economic blocs is assuaging concerns that the global economy is sliding into an inevitable slowdown and recession.

Spotlight

Kameda Arabia

Kameda Arabia (KA) is a Joint Venture between Dr. Soliman Fakeeh Holding company, Jeddah and Kameda Infologics Pvt Ltd based in Japan, India and local support offices in USA, UK, UAE and Malaysia. Dr. Soliman Fakeeh is a renowned name in the Saudi Arabia Healthcare Market from past three decade. Having its Business in Healthcare, Education, Medical Item Supply's and Wellness. Kameda Infologics Pvt Ltd (KI) is a provider of integrated IT solutions to the healthcare industry and has strived to develop world-class software products specializing in Healthcare. Dr. Toshitada Kameda, founder of Kameda Informatics Ltd. is a pioneer in the development of paperless solutions and is currently rendering its service to more than 200 hospitals in Japan. It was Dr. Kameda’s vision which made Kameda Medical Center a 1000 bedded super specialty hospital, south of Tokyo, into a paperless and filmless facility since 1994. KI is using the best practices, systems and quality procedures for its software de

OTHER ARTICLES
MedTech

Biotech in 2022

Article | October 7, 2022

The robust global channel of more than, 800 gene and cell curatives presently in trials will produce clinical readouts in 2022, revealing what lies ahead for advanced curatives. The impact will be felt in 2022, no matter how you slice it. Eventually, how well industry and non-supervisory bodies unite to produce new frameworks for advanced therapies will shape the year 2022 and further. Pacific Northwest talent will continue to contribute to the advancement of gene and cell curatives in both the short and long term, thanks to its deep pool of ground-breaking scientific developers, entrepreneurial directorial leadership, largely skilled translational scientists, and endured bio manufacturing technicians. We may see continued on-life science fund withdrawal from biotech in 2021, but this can be anticipated as a strong comeback in 2022 by biotech industry, backed by deep-pocketed life science investors who are committed to this sector. A similar investment, combined with pharma's cash-heavy coffers, can result in increased junction and acquisition activity, which will be a challenge for some but an occasion for others. Over the last five years, investment interest in Seattle and the Pacific Northwest has grown exponentially, from Vancouver, British Columbia, to Oregon. The region's explosive portfolio of new biotech companies, innovated out of academic centres, demonstrates the region's growing recognition of scientific invention. This created a belief that continued, especially because Seattle's start-ups and biotech enterprises are delivering on their pledge of clinical and patient impact. Talent and staffing will continue to be difficult to find. It's a CEO's market, but many of these funds' return, and are not rising in proportion to the exorbitant prices they're paying to enter deals. This schism has become particularly pronounced in 2021. Hence, everyone in biotech is concerned about reclamation and retention.

Read More
MedTech

2022 U.S. Market Research Report with COVID-19 Forecasts2

Article | July 12, 2022

The global biotechnology market is expected to grow at a compound annual growth rate (CAGR) of 13.9 percent from 2022 to 2030, with a value estimated at USD 1,023.92 billion in 2021. The market is being propelled by strong government support in the form of initiatives aimed at modernizing the regulatory framework, improving approval processes and reimbursement policies, and standardizing clinical studies. The growing presence of personalized medicine and an increasing number of orphan drug formulations are opening up new avenues for biotechnology applications and driving the influx of emerging and innovative biotechnology companies, which is driving market revenue even further. The 2022 Biotech Research and Development Market Research Report is one of the most comprehensive and in-depth assessments of the industry in the United States, containing over 100 data sets spanning the years 2013 to 2026. This Kentley Insights report contains historical and forecasted market size, product lines, profitability, financial ratios, BCG matrix, state statistics, operating expense details, organizational breakdown, consolidation analysis, employee productivity, price inflation, pay bands for the top 20 industry jobs, trend analysis and forecasts on companies, locations, employees, payroll, and much more. Companies in the Biotech Research and Development industry are primarily engaged in biotechnology research and experimental development. Biotechnology research and development entails the investigation of the use of microorganisms and cellular and bimolecular processes to create or modify living or non-living materials. This biotechnology research and development may result in the development of new biotechnology processes or prototypes of new or genetically altered products that can be replicated, used, or implemented by various industries. This report was created using the findings of extensive business surveys and econometrics. The professionals follow reports with accurate and apt information on market sizing, benchmarking, strategic planning, due diligence, cost-cutting, planning, understanding industry dynamics, forecasting, streamlining, gap analysis, and other ana

Read More
Medical

Wisconsin biotech companies could play key roles in long-term economic recovery from COVID-19 pandemic

Article | July 14, 2022

Whether it’s called a modern “Manhattan Project” or a medical moon shot, the concept of long-term economic recovery rests on how confident people are they won’t risk serious illness by venturing forth in public again. Wisconsin stands to be a significant part of such an undertaking, whatever it’s called. The shorter-term debate is well under way over the gradual lifting of COVID-19 emergency rules, such as the now-extended “safer-at-home” order in Wisconsin. At least a dozen states, including regional coalitions on the East and West coasts, are exploring next steps as they seek to balance responses to the virus with calls for reopening the economy, at least, in part. Wisconsin’s ability to shape longer-term responses will come from private and public resources, which range from companies engaged in production of diagnostics.

Read More
MedTech

Expansion of BioPharma: Opportunities and Investments

Article | July 12, 2022

Biopharmaceutical innovations are among the most ingenious and refined achievements of modern medical science. New concepts, techniques, and therapies are emerging, such as the cell therapy Provenge, which can be used to treat cancer, and gene therapies, which provide even more amazing promises of disease remission and regenerative medicine. In addition, the COVID-19 pandemic has caused a huge boom in the pharmaceutical industry. This is because more and more attention is being paid to increasing manufacturing capacity and starting new research on drug development. Biopharma: Leading the Way in the Pharma Sector In the past couple of years, the biopharmaceutical sector has deepened its roots across the medical and pharmaceutical industries, on account of the transformation of pharmaceutical companies towards biotechnology, creating opportunities for growth. Also, growing advancements in technologies such as 3D bioprinting, biosensors, and gene editing, along with the integration of advanced artificial intelligence and virtual and augmented reality are estimated to further create prospects for growth. According to a study, the biopharmaceutical sector makes nearly $163 billion around the world and grows by more than 8% each year, which is twice as fast as the traditional pharma sector. Massive Investments Directed Towards Biopharma Investing in biotech research and development (R&D) has yielded better returns than the pharma industry average. Hence, a number of pharmaceutical companies are shifting their presence toward biopharma to capitalize on the upcoming opportunities by investing in and expanding their biotechnology infrastructure. For instance, Thermo Fisher Scientific Inc., an American manufacturer of scientific instrumentation, reagents and consumables, and software services, announced an investment of $97 million to expand its bioanalytical laboratory operations into three new locations in the U.S. With this investment, the company will add 150,000 square feet of scientific workspace and install the most advanced drug development technologies to produce life-changing medicines for patients in need.

Read More

Spotlight

Kameda Arabia

Kameda Arabia (KA) is a Joint Venture between Dr. Soliman Fakeeh Holding company, Jeddah and Kameda Infologics Pvt Ltd based in Japan, India and local support offices in USA, UK, UAE and Malaysia. Dr. Soliman Fakeeh is a renowned name in the Saudi Arabia Healthcare Market from past three decade. Having its Business in Healthcare, Education, Medical Item Supply's and Wellness. Kameda Infologics Pvt Ltd (KI) is a provider of integrated IT solutions to the healthcare industry and has strived to develop world-class software products specializing in Healthcare. Dr. Toshitada Kameda, founder of Kameda Informatics Ltd. is a pioneer in the development of paperless solutions and is currently rendering its service to more than 200 hospitals in Japan. It was Dr. Kameda’s vision which made Kameda Medical Center a 1000 bedded super specialty hospital, south of Tokyo, into a paperless and filmless facility since 1994. KI is using the best practices, systems and quality procedures for its software de

Related News

European Biotechs Showcase Multiple Sclerosis Treatments in Stockholm

Labiotech.eu | September 17, 2019

Genmab, GeNeuro and other companies presented their latest data on next-generation treatments for multiple sclerosis at a conference in Stockholm. The European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) gathered experts and companies working on multiple sclerosis in Sweden this year. Companies such as Genmab and GeNeuro revealed the progress of their treatments, with Genmab’s drug at the verge of reaching the market. Multiple sclerosis is a neurological autoimmune condition where the immune system attacks the cells that keep nerve cells healthy, causing neurodegeneration and eventual disability. Its has received attention from the biotech industry because the condition has no cure, and there are limited drugs approved to slow the progression of the disease. In particular, many companies aim to stop relapses in the most common form of the condition, known as relapsing-remitting multiple sclerosis. The Danish antibody developer Genmab presented results from its drug ofatumumab, which is licensed to Novartis. In two phase III trials, the ability of the antibody drug to prevent relapse was compared to that of teriflunomide, an oral drug routinely used to treat relapsing forms of multiple sclerosis. Patients given Genmab and Novartis’ antibody had an annualized relapse rate of around 0.1 in the two trials, which is less than half of those given teriflunomide in both trials, with an annualized relapse rate of around 0.22.

Read More

Fund for Late-Stage European Biotechs Closes Final Round With 120M Euors

labiotech.eu | June 25, 2019

The Luxembourg-based investor Vesalius Biocapital III has completed the final closing of a €120M fund to boost late-stage life science companies. Around 10-15 companies will receive investments from the fund, including specialists in drug development, med-tech, and diagnostics. Three companies have become beneficiaries so far, including the Finnish women’s health drug company Forendo Pharma, German prosthetics company Mecuris, and US digital therapy company SWORD Health. Vesalius Biocapital has secured more than €65M for the first closing of a new fund targeting European biotechs in late stages of development. Vesalius Biocapital has announced today the first closing of its third fund, VBC III, which will be aimed at biotech companies developing not only drugs and diagnostics, but also medtech and digital health products. Unlike the first two funds, VBC III will focus the investments on companies at late stages of development and closer to the market. The first closing has secured Vesalius over €65M. Over the following 18 months, the investment firm is aiming to reach €150M for the final closing. This objective is way higher than for previous funds, but the number of companies invested in, 10 to 15, will not increase; late development stages require bigger injections.

Read More

Ocular Biotechs Histogenics, Ocugen Announce Stock-For-Stock Merger

Histogenics Corporation | April 08, 2019

Histogenics Corporation and privately held Ocugen announced a merger Monday that will create a new, Nasdaq-listed company aiming to develop novel ocular gene therapies and biotherapeutics under the Ocugen name. The agreement calls for Ocugen stockholders to become the majority owners of outstanding Histogenics common stock upon closing. The deal is a stock-for-stock transaction. Upon closing, the combined company will be headquartered in Malvern, Pennsylvania and will operate under Ocugen's present leadership, the companies said. No Histogenics employees will remain employed by the combined company, according to Monday's announcement.

Read More

European Biotechs Showcase Multiple Sclerosis Treatments in Stockholm

Labiotech.eu | September 17, 2019

Genmab, GeNeuro and other companies presented their latest data on next-generation treatments for multiple sclerosis at a conference in Stockholm. The European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) gathered experts and companies working on multiple sclerosis in Sweden this year. Companies such as Genmab and GeNeuro revealed the progress of their treatments, with Genmab’s drug at the verge of reaching the market. Multiple sclerosis is a neurological autoimmune condition where the immune system attacks the cells that keep nerve cells healthy, causing neurodegeneration and eventual disability. Its has received attention from the biotech industry because the condition has no cure, and there are limited drugs approved to slow the progression of the disease. In particular, many companies aim to stop relapses in the most common form of the condition, known as relapsing-remitting multiple sclerosis. The Danish antibody developer Genmab presented results from its drug ofatumumab, which is licensed to Novartis. In two phase III trials, the ability of the antibody drug to prevent relapse was compared to that of teriflunomide, an oral drug routinely used to treat relapsing forms of multiple sclerosis. Patients given Genmab and Novartis’ antibody had an annualized relapse rate of around 0.1 in the two trials, which is less than half of those given teriflunomide in both trials, with an annualized relapse rate of around 0.22.

Read More

Fund for Late-Stage European Biotechs Closes Final Round With 120M Euors

labiotech.eu | June 25, 2019

The Luxembourg-based investor Vesalius Biocapital III has completed the final closing of a €120M fund to boost late-stage life science companies. Around 10-15 companies will receive investments from the fund, including specialists in drug development, med-tech, and diagnostics. Three companies have become beneficiaries so far, including the Finnish women’s health drug company Forendo Pharma, German prosthetics company Mecuris, and US digital therapy company SWORD Health. Vesalius Biocapital has secured more than €65M for the first closing of a new fund targeting European biotechs in late stages of development. Vesalius Biocapital has announced today the first closing of its third fund, VBC III, which will be aimed at biotech companies developing not only drugs and diagnostics, but also medtech and digital health products. Unlike the first two funds, VBC III will focus the investments on companies at late stages of development and closer to the market. The first closing has secured Vesalius over €65M. Over the following 18 months, the investment firm is aiming to reach €150M for the final closing. This objective is way higher than for previous funds, but the number of companies invested in, 10 to 15, will not increase; late development stages require bigger injections.

Read More

Ocular Biotechs Histogenics, Ocugen Announce Stock-For-Stock Merger

Histogenics Corporation | April 08, 2019

Histogenics Corporation and privately held Ocugen announced a merger Monday that will create a new, Nasdaq-listed company aiming to develop novel ocular gene therapies and biotherapeutics under the Ocugen name. The agreement calls for Ocugen stockholders to become the majority owners of outstanding Histogenics common stock upon closing. The deal is a stock-for-stock transaction. Upon closing, the combined company will be headquartered in Malvern, Pennsylvania and will operate under Ocugen's present leadership, the companies said. No Histogenics employees will remain employed by the combined company, according to Monday's announcement.

Read More

Events